Research focused on the differences in the ways males and females process GHB could lead to better understanding of overdose risk.
Dr. Melanie A. Felmlee, an assistant professor of pharmaceutics and medicinal chemistry at University of the Pacific’s Thomas J. Long School of Pharmacy, has received a four-year, $1.15 million grant for research that focuses on the differences in the way males and females process GHB. The grant is from the National Institutes of Health Support of Competitive Research (SCORE) Program for her project “GHB Toxicokinetics: Role of sex hormone dependent monocarboxylate transporter regulation and potential for altered overdose risk in transgender men and women.” The SCORE Research Advancement Award is co-funded by the National Institute of General Medical Sciences and the National Institute on Drug Abuse.
Dr. Melanie A. Felmlee, an assistant professor of pharmaceutics and medicinal chemistry at University of the Pacific’s Thomas J. Long School of Pharmacy, has received a four-year, $1.15 million grant for research that focuses on the differences in the way males and females process GHB. The grant is from the National Institutes of Health Support of Competitive Research (SCORE) Program for her project “GHB Toxicokinetics: Role of sex hormone dependent monocarboxylate transporter regulation and potential for altered overdose risk in transgender men and women.” The SCORE Research Advancement Award is co-funded by the National Institute of General Medical Sciences and the National Institute on Drug Abuse.
“This grant provides the support to significantly enhance and accelerate the research conducted in my lab at University of the Pacific,” Felmlee said. “With this research we hope to understand why GHB toxicity is different in males and females, inclusive of all at-risk populations.” Felmlee is passionate about bringing awareness through her research to underserved populations that are at risk.
“I think when we design any study we should be inclusive,” Felmlee said. “While we are trying to look at the whole spectrum, we are focusing on the transgender population, which has largely been overlooked in GHB research studies.” The research has the potential for broader application. “The monocarboxylate transporters I study are also involved in targeted therapeutic strategies for oncology, fertility studies and immune suppression,” she continued. “Changes in these transporters in response to sex hormones has the potential to impact these broader fields of research.”
Felmlee’s research focuses on the role of sex differences on transporter regulation and toxicity of drugs. Her research on GHB suggests females are protected from toxicity, compared to males, because of the hormones estrogen and progestogen. This research will look at specific proteins that transport GHB across cell membranes and their regulation by sex hormone therapy.
“The transporters are regulated by sex hormones,” Felmlee said. “They are critical for determining how one’s kidney functions in terms of removing the drug. What my graduate research assistants and I have found is females at certain times in their reproductive cycle are more protected from GHB toxicity and they were able to remove the drug faster. The transporters are the key to figuring out why there are the differences associated with the sex hormones.”
GHB, or gamma-hydroxybutyrate, is a central nervous system depressant clinically prescribed to treat the medical conditions narcolepsy and cataplexy. It is also an illicit drug taken for its calming and euphoric effects, which make it a popular drug of abuse. In clinical doses it is safe. In comparison, illicit GHB is colorless and odorless, which makes it difficult to determine the dose, significantly increasing the risk of overdose.